Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

doi: 10.1093/ecco-jcc/jjx133

In the above mentioned article a number of minor errors have been identified by the authors within some of the patient-reported outcome (PRO) data reported in the manuscript. These are summarised below:

There is an error within the coded Inflammatory Bowel Disease Questionnaire (IBDQ) PRO data for the tofacitinib ulcerative colitis Phase 3 studies reported in the article (induction studies: OCTAVE Induction 1 and 2; and maintenance study: OCTAVE Sustain). This data extraction error resulted in incorrect IBDQ data being presented.

The error does not affect the overall conclusions regarding IBDQ, as the corrected summary data retain statistical significance and the difference between the corrected and erroneous numbers is in general small. The error was specific to IBDQ data; all other PRO measures and questionnaire-based data (e.g. component of the Mayo Score) have been reviewed and are correct as reported.

The affected IBDQ data have been corrected in the Abstract on page 145, on page 148 (Table 1), in the text on page 149 and in Figure 1, in Tables 2 and 3 and the text on page 150 and in Figure 2 on page 51. The Supplementary Tables 1–4 and 7–8 have also been corrected.

Figure 1.

Figure 2.

The authors apologise for these errors.